Review
The double-edged sword of COX-2 selective NSAIDs
James M. Wright
CMAJ November 12, 2002 167 (10) 1131-1137;
James M. Wright
Dr. Wright is with the Departments of Pharmacology and Therapeutics and of Medicine, University of British Columbia, Vancouver Hospital, UBC site, Vancouver, BC
Submit a Response to This Article
Jump to comment:
No Responses have been published for this article.
In this issue
Article tools
The double-edged sword of COX-2 selective NSAIDs
James M. Wright
CMAJ Nov 2002, 167 (10) 1131-1137;
Jump to section
- Article
- Abstract
- Pharmacology of NSAIDs
- Benefits of NSAIDs
- Harms of NSAIDs
- Potential advantages of COX-2 selective NSAIDs
- Potential disadvantages of COX-2 selective NSAIDs
- Benefits and harms of COX-2 selective NSAIDs from large randomized controlled trials
- Why do COX-2 selective NSAIDs increase nongastrointestinal serious adverse events?
- Results of the CLASS and VIGOR trials may be explained by COX-2 selectivity
- Is the increased harm caused by COX-2 selective NSAIDs a dose-related phenomenon?
- Conclusions and suggested future trials
- Footnotes
- References
- Figures & Tables
- Responses
- Metrics
Related Articles
Cited By...
- Disruption of Cholesterol Efflux by Coxib Medications and Inflammatory Processes: Link to Increased Cardiovascular Risk
- Nitric oxide deficiency promotes vascular side effects of cyclooxygenase inhibitors
- Balancing the cyclooxygenase portfolio.
- COX-2 inhibitors and the heart: are all coxibs the same?
- Glia as a Therapeutic Target: Selective Suppression of Human Amyloid-beta-Induced Upregulation of Brain Proinflammatory Cytokine Production Attenuates Neurodegeneration
- Risk of adverse gastrointestinal outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis
- Nonsteroidal Antiinflammatory Drugs: A Review
- Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis
- Are All COX-2 Inhibitors Created Equal?
- Coxib medications to be handled with care
- Non-steroidal anti-inflammatory drugs, including cyclo-oxygenase-2 inhibitors, in osteoarthritic knee pain: meta-analysis of randomised placebo controlled trials
- The eicosanoid cascade: possible role in gliomas and meningiomas
- Why don't we initiate more large simple randomized controlled trials?
- COX-2 inhibitors and type 4 error
- Seeking disclosure
- Seeking disclosure
- POEM: Harms outweigh benefits of COX 2 for many patients